Table 1 Baseline characteristics
From: Clinical covariates influencing clinical outcomes in primary membranous nephropathy
Group | Covariate | Subjects (N) | Valuea |
|---|---|---|---|
General characteristics | Female sex (N) | 74 | 24.00 (32.43%) |
Age (years) | 74 | 59.50 (46.50, 70.00) | |
follow-up (months) | 74 | 30.50 (7.25, 73.75) | |
time since diagnosis (biopsy; months) | 74 | 0.00 (0.00, 5.00) | |
Renal parameters | eGFR (ml/min/1.73m2) | 74 | 55.52 (30.48, 84.09) |
UPCR (g/g) | 74 | 5.97 (4.23, 9.27) | |
Albumin (g/dl) | 74 | 2.85 (2.50, 3.30) | |
Lipids | Cholesterol (mg/dl) | 48 | 266.75 (230.75, 353.50) |
Triglycerides (mg/dl) | 41 | 183.00 (138.00, 277.00) | |
HDL-Cholesterol (mg/dl) | 38 | 56.00 (46.25, 76.25) | |
LDL-Cholesterol (mg/dl) | 38 | 173.12 (132.00, 228.25) | |
ACEI ARB treatment | ACEI/ARB treatment (N) | 53.00 (71.62%) | |
ACEI equivalent (Ramipril [mg]) | 43 | 10.00 (5.00, 10.00) | |
ARB equivalent (Candesartan [mg]) | 16 | 16.00 (16.00, 40.00) | |
Immunosuppression | |||
Prednisone therapy | Prednisone treatment (N) | 22.00 (29.73%) | |
Prednisone dose (mg) | 22 | 20.00 (15.00, 34.38) | |
Rituximab therapy | Rituximab treatment (N) | 18.00 (24.32%) | |
Rituximab dose (mg) | 18 | 1,000.00 (1,000.00, 1,000.00) | |
Cyclophosphamide therapy | Cyclophosphamide treatment (N) | 18.00 (24.32%) | |
Cyclophosphamide sum dose (mg) | 18 | 2,900.00 (2,041.25, 4,063.75) | |
MMF therapy | MMF treatment (N) | 2.00 (2.70%) | |
MMF dose (mg) | 2 | 1,500.00 (1,250.00, 1,750.00) | |